The Quality Lowdown: Recalls And Shortages

EpiPens get new lease on life, though not like nationally stockpiled AtroPens got, while B. Cepacia humbles King Bio and valsartan impurity rouses science to action. More drug recalls, more warning letters, more import alerts are announced, while a new counterfeit detector makes its debut.